Kham Ung, DPM
Foot & Ankle Surgery · Sioux City, IANPI 1205937554
Payments from drug & device makers
What this record shows
Smith+Nephew accounts for 61.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $1,597 and has fallen 87.0% since, to $207 in 2025.
Across 99 payments — averaging $43.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Paragon 28, Inc.$1K
- Musculoskeletal Transplant Foundation Inc.$220
- Solventum Corporation$80
- Mimedx Group, Inc.$66
- Paratek Pharmaceuticals, Inc.$59
- plus $217 from 8 others
What the payments were for
- Travel & lodging$2,05247%
- Food & beverage$2,27953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 73 | $2,676 |
| Paragon 28, Inc. | 5 | $1,013 |
| Musculoskeletal Transplant Foundation Inc. | 4 | $220 |
| Solventum Corporation | 2 | $80 |
| Mimedx Group, Inc. | 3 | $66 |
| Paratek Pharmaceuticals, Inc. | 3 | $59 |
| Amgen | 1 | $46 |
| Urgo Medical North America, LLC | 1 | $32 |
| Vertex | 1 | $29 |
| Merck | 2 | $27 |
| Biotissue Holdings Inc. | 1 | $25 |
| Osiris Therapeutics Inc. | 1 | $25 |
| Polynovo North America LLC | 1 | $18 |
| Kerecis Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Grafix$1,165
- STRAVIX PL$1,059
- Oasis$789
- Versajet$715
- GRAFIX PL$376
- Stravix$376
- STRAVIX MESH$109
How this compares
$4,330 in reported general payments places this provider in the 60th percentile of 112 foot & ankle surgery providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 45 | $1,271 |
| Doxycycline Monohydrate | 18 | $858 |
| Metronidazole | 14 | $321 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $230 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $200 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $71 |
| Gabapentin | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Sioux City
- Phinit PhisitkulSioux City$1.4M
- Valerie Tallerico-AntonopoulosSioux City$9K
- Kostadinos AntonopoulosSioux City$8K
- Michael LeeDes Moines$2.1M
- Sean GrambartDes Moines$590K
- Kelsey MillonigDes Moines$330K
- Charles CibulaCedar Falls$38K
- Gregory FooteWaterloo$35K
- Nathan ShumwayCouncil Bluffs$33K
- Justin RaatzDes Moines$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.